Abbot Labs (ABT) To Transfer TriCor Rights to Teva Pharma (TEVA) as Soon as 2011
More News related to ABT
- Abbott (ABT) Seeks for ARCHITECT HE4 to be First Automated HE4 Test Available in the U.S.
- Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
- Health Discovery Corporation Partners with Major New York City Pancreatic Cancer Center to Develop a New Molecular Diagnostic Test for the Early Detection of Pancreatic Cancer
- First Global Upgrades Abbot Labs (ABT) to Long Term Outperform
- Absolute Software's Computer Lifecycle Management Solution Selected by University of Texas
More News related to TEVA
- BioSante Pharmaceuticals Appoints Jeffrey W. Winkelman, Ph.D., J.D., Vice President, Oncology Programs
- Teva Pharma (TEVA) Extends Oral Laquinimod Marketing and Distribution Rights to Nordic and Baltic Regions
- Teva Acquires Marketing Rights for Oral Laquinimod in the Nordic and Baltic Regions
- Teva Pharma (TEVA) Settles with Ven-A-Care; To Record Charge of $315M for Q409
- Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits
More News related to Corporate News
- AAR (AIR) Predicts Impact of Mesa's Bankruptcy on Q3 Results
- AspenBio Pharma (APPY) Reports Results from Interim Analysis for Ongoing Trial of AppyScore
- TheStreet.com (TSCM) Regains NASDAQ Compliance
- S&P Lowers Pinnacle Entertainment (PNK) Outlook from Stable to Negative
- AeroVironment (AVAV) Awarded $17.1M Army Contract for Raven Unmanned Aircraft System
Abbot Labs (NYSE: ABT) and Laboratories Fournier SA may give rights for cholesterol fighter TriCor to Teva Pharmaceutical Labs (NASDAQ: TEVA).
An 8-K was filed with the U.S. Securities and Exchange Commission indicating the transfer of intellectual property rights no sooner than March 28, 2011. Teva may not gain those rights until July 12, 2012 under certain circumstances, the filing reports.
Related Categories
Corporate NewsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
